Urothelial cancer: advances, innovation and improving outcomes

Join the Royal Society of Medicine (RSM) Urology Section for this one-day meeting exploring the latest advances in urothelial cancer care. Bringing together leading urologists, oncologists and researchers, the programme will examine developments across the bladder cancer pathway, from diagnosis and transurethral resection of bladder tumour (TURBT) to bladder-sparing treatments, robotic surgery and new systemic therapies.

The management of urothelial cancer is undergoing a period of rapid change. Advances in diagnostics, surgical techniques and systemic treatments are creating new opportunities to improve outcomes, while increasing emphasis is being placed on quality improvement, personalised treatment pathways and reducing disparities in care. This meeting will provide practical updates on contemporary management and explore how emerging evidence is shaping clinical practice.

Through expert-led presentations, case discussions and multidisciplinary debate, delegates will explore quality improvement in TURBT, advances in bladder-sparing treatment, innovations in muscle-invasive and metastatic disease management, and evolving approaches to upper tract urothelial cancer. The programme will also examine disparities in outcomes for female patients and consider strategies to improve counselling and care.

Why attend?

• Hear from leading experts including Professor Param Mariappan, Professor Tom Powles, Professor Ben Challacombe and Professor Alison Birtle
• Explore how quality improvement initiatives, including lessons from Scotland's bladder cancer KPI programme, are shaping care delivery.
• Gain updates on bladder-sparing approaches for non-muscle-invasive and muscle-invasive bladder cancer
• Learn about emerging systemic therapies and advances in the management of metastatic urothelial cancer
• Examine current approaches to upper tract urothelial cancer, including nephron-sparing strategies and robotic surgery
• Explore disparities in bladder cancer outcomes and the impact of treatment on female patients

Aims of the event

• Provide an update on contemporary management strategies for urothelial cancer
• Explore advances in diagnostics, surgery and systemic treatments across the bladder cancer pathway
• Support clinicians in applying emerging evidence and best practice to improve patient outcomes

Learning outcomes
By attending this meeting, participants will be able to:

• Describe the key components of high-quality TURBT and their role in bladder cancer management
• Evaluate current bladder-sparing treatment options for non-muscle-invasive and muscle-invasive bladder cancer
• Assess recent developments in upper tract urothelial cancer management, including surgical and systemic approaches
• Apply learning from contemporary evidence and multidisciplinary discussion to improve patient care
• Recognise disparities in bladder cancer outcomes between male and female patients and consider strategies to improve counselling and care.

Who should attend?
This meeting is suitable for:

• Urologists and urology specialists
• Oncologists involved in the management of urothelial cancer
• Consultants, GPs, SAS doctors and resident doctors with an interest in urological oncology
• Clinical nurse specialists and allied health professionals involved in bladder cancer care
• Researchers and healthcare professionals with an interest in urothelial cancer and surgical innovation

Follow us on: 

Facebook 
Instagram 
LinkedIn 
Twitter 
YouTube